Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability

Bioorg Med Chem. 2010 Feb;18(3):1045-53. doi: 10.1016/j.bmc.2009.12.052. Epub 2010 Jan 6.

Abstract

Isosorbide-2-carbamate-5-esters are highly potent and selective butyrylcholinesterase inhibitors with potential utility in the treatment of Alzheimer's Disease (AD). They are stable in human plasma but in mouse plasma they undergo hydrolysis at the 5-ester group potentially attenuating in vivo potency. In this paper we explore the role of the 5-position in modulating potency. The focus of the study was to increase metabolic stability while preserving potency and selectivity. Dicarbamates and 5-keto derivatives were markedly less potent than the ester class. The 2-benzylcarbamate-5-benzyl ether was found to be potent (IC(50) 52 nM) and stable in the presence of mouse plasma and liver homogenate. The compound produces sustained moderate inhibition of mouse butyrylcholinesterase at 1mg/kg, IP.

MeSH terms

  • Alzheimer Disease / drug therapy
  • Animals
  • Butyrylcholinesterase / metabolism*
  • Cholinesterase Inhibitors / chemistry
  • Cholinesterase Inhibitors / metabolism*
  • Cholinesterase Inhibitors / pharmacology*
  • Humans
  • Isosorbide / chemistry
  • Isosorbide / metabolism*
  • Isosorbide / pharmacology*
  • Mice
  • Molecular Structure
  • Plasma / metabolism
  • Structure-Activity Relationship

Substances

  • Cholinesterase Inhibitors
  • Butyrylcholinesterase
  • Isosorbide